Science & Technology

With an eye on innovation™

we deliver first-in-class solutions and technologies to provide a brighter future for those at risk of losing their sight. EyePoint specializes in the development of sustained-release drug delivery to treat debilitating diseases of the eye and other localized, chronic conditions.

Vorolanib - Selective and Potent Pan-VEGF Receptor Inhibitor

  • Composition of matter patent into 2037
  • Previous Phase 1 and Phase 2 clinical trials in wet AMD as an oral therapy showed compelling efficacy data with no ocular toxicity observed1,2
  • In-vivo studies demonstrate encouraging neuroprotection data and potential anti-fibrosis effect3
  • Reduced off-target binding of receptors associated with systemic side effects of kinase inhibitors (TKIs)
  • Vorolanib inhibits pathways with key roles in angiogenesis and pathological vascular leakage
    • Potent and selective pan–VEGF receptor inhibitor
    • Does not inhibit TIE2 receptors at clinically relevant doses
  • Acts intracellularly and inhibits proangiogenic signaling


Safe Sustained IVT Drug Delivery

  • Used in four of six FDA approved intravitreal sustained delivery products
  • Delivered by a single in-office IVT injection
  • Continuous, stable release of drug with zero-order kinetics

Durasert E™: bioerodible

  • Non-erodible polyimide coating removed
  • Bioerodible matrix is designed to deplete drug load before fully eroding

Durasert®: non-erodible

  • YUTIQ® (Alimera)
  • ILUVIEN® (Alimera)


Verisome® technology is a novel, sustained-delivery platform


  • Biodegradable liquid in aqueous sphere
  • Customizable duration from one week to several months


DEXYCU is approved for the treatment of inflammation following ocular surgery.

Partnerships and BD Initiatives

EyePoint technologies have broad applicability across many therapeutic areas. Our validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. EyePoint seeks additional strategic partners to collaborate on the development of new sustained-release drug suspensions and inserts, to access complementary research, and to expand our product portfolio.

References: 1. Jackson et al. JAMA Ophthalmol 2017. 2. Cohen MN et al. Br J Ophthalmol. 2021. 3. ARVO 2023 Presentation.